Consun Pharmaceutical Group Limited (01681) reported no changes in its authorized share capital for February 2026, remaining at 5,000,000,000 ordinary shares at HKD 0.1 par value each, with total authorized share capital at HKD 500.00 million.

At the end of February 2026, the total issued shares (excluding treasury shares) decreased from 841,508,111 to 841,423,111, reflecting a net decrease of 85,000. This net change comprised 15,000 shares newly issued under a share option exercise and a redemption of 100,000 shares. The share option exercise contributed HKD 60,150.00 in proceeds. The issuer confirmed that the public float requirement of 25% continues to be met.